PP112. GENE POLYMORPHISMS IN THE INTERLEYKIN-1 LOCUS AND THE RISK OF MYOCARDIAL INFARCTION G. TULYAKOVA ¹, T. Nasibullin ¹, A. Zakirova ², E. Khusnutdinova ¹, O. Mustafina ¹, A. Salmanov ³
¹Institute of Biochemistry and Genetics, Ufa Research Center, Russian Academy of Sciences, Ufa, Russia ²Cardiology Department, Bashkir State Medical University, Ufa, Russia ³ Bureau of Judicial Medical Examination of Bashkortostan, Ufa, Russia
e-mail: gulnarat@mail.ru
*Corresponding Author: page: 98
|
Abstract
There is growing evidence that interleukin-1 (IL-1) plays an important role in the pathogenesis of atherosclerosis and myocardial infarction (MI). The present study examined whether molecular variations at the IL-1 locus are involved in predisposition to MI in Russians and Tatars of Bashkortostan. We examined the frequencies of three polymorphisms: IL-1 β (-511) a C→T single base transition, IL-1β (+3953) a C→T transition in exon 5, and IL-1 antagonist receptor (IL-1RN) a variable number tandem repeat (VNTR) in intron 2 of the gene in 306 male patients with MI and 245 healthy controls. The genotype and allele frequencies in the Russian and Tatar control groups from Bashkortostan were consistent with those predicted by the Hardy-Weinberg equilibrium. We found no significant differences in the genotype or allele frequencies in each of these three polymorphisms between Russian and Tatar patients with MI and healthy control individuals. No associations were found between IL1RN VNTR polymorphism and MI patients divided into the three groups according to their body mass index (BMI). The frequencies of the IL-1 β /-511 CT genotype (p=0.013) in Tatar patients with BMI of >30kg/m² were higher and of the CC genotype lower (P=0.041) than in the Tatar control group. In the Russian patients with BMI of >30 frequencies of the IL-1 β /+3954 T allele (P=0.026) and TT genotype (P=0.014) were significantly higher than in the Russian controls. This study shows that the +3953 (C→T) and -511 (C→T) IL-1 β gene polymorphisms may be a genetic risk factor for the development of MI in patients with a BMI of >30.
|
|
|
|
|
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|